SIL declares profit from operations growth as +6% vs previous year

Published On 2025-08-03 06:00 GMT   |   Update On 2025-08-03 06:00 GMT
Advertisement

Mumbai: Sanofi India Limited has announced its financial results for the quarter ended June 30, 2025.

The Company recorded a 9% decline in net sales on a comparable basis of continuing business. In the Domestic market, the successful launch of Soliqua, its diabetes treatment for the premix segment, continues to gain momentum, reinforcing the company's comprehensive diabetes portfolio. Toujeo maintained strong performance with high single-digit growth.

The company's strategic partnerships in Cardiovascular (CV) and Central Nervous System (CNS) segments have established a solid foundation, meeting expectations for market reach expansion and business acceleration.

Export sales were affected by non-recurring CHC product sales from 2024 and the planned discontinuation of the Zentiva portfolio.

For the year-to-date period ended June 2025, the Company achieved a 6% increase in operating profit.

Advertisement

Rachid Ayari, Whole Time Director and Chief Financial Officer said,  "During this transformative year for our company, our insulin portfolio has demonstrated robust growth, led by Toujeo and the successful introduction of Soliqua - our premium diabetes solution for the premix segment. Our strategic partnerships have effectively expanded our reach to healthcare professionals in both CV (Cardiovascular) and CNS (Central Nervous System) therapeutic areas, meeting our planned objectives. Moving forward, we remain committed to enhancing operational efficiency while broadening access to both our established products and innovative therapies across India."

Sanofi India’s world-class manufacturing site in Goa produces for people in India and 60+ other countries. Sanofi has located one of its four global talent hubs in Hyderabad, India, from where wide range of services are provided globally. Recognized by the ‘Top Employers Institute’ – a global authority that honours excellence in people practices since 2019, Sanofi’s local entities include Sanofi India Limited (SIL - listed entity), and Sanofi Healthcare India Pvt. Ltd. (SHIPL).

Read also: Sanofi India ropes in Sudipta Chakraborty as Head of Legal, India

Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News